Innovent Biologics

Eli Lilly has transferred sales rights for the breast cancer drug Verzenios in mainland China to Innovent Biologics. Innovent will manage importing, marketing, and distribution as generic competition emerges.

An FDA advisory panel recommended updating fall 2023 Covid vaccines to target the XFG variant. Pfizer and China’s Innovent Biologics announced a $10.5 billion global collaboration to develop 12 early-stage cancer drugs. The WHO fast-tracked three existing drugs for testing against the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo.

China’s Innovent Biologics has signed a $10.5 billion global collaboration with Pfizer to develop 12 cancer treatment programs. The deal includes an upfront payment of $650 million and potential milestone payments totaling up to $9.85 billion.

Innovent Biologics and Pfizer have signed a $10.5 billion collaboration to develop 12 cancer treatment programs. Innovent will receive an upfront payment of $650 million and up to $9.85 billion in milestone payments tied to development, regulatory, and commercial goals.

Innovent Biologics' shares increased by 10% following a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines, with the pact valued up to $10.5 billion.

China's Innovent Biologics has signed a drug deal with Pfizer worth up to $10.5 billion. The agreement involves collaboration on a cancer immunotherapy drug.